{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014743","form_type":"8-K","ticker":null,"cik":"0000764195","company_name":"VBI Vaccines Inc/BC","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.928372+00:00","generated_at":"2026-06-03T22:38:16.563444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VBI Vaccines FY 2023 revenue $8.7M, net loss $92.8M; PreHevbrio sales up 234%","bullets":["PreHevbrio net revenue $3.1M in 2023, up 234% YoY; Q1 2024 US volume ~65% of FY2023.","VBI-1901 Phase 2b in GBM: 40% disease control (2/5 stable) vs 0% control; more data mid/year-end 2024.","Agreement to sell Rehovot manufacturing to Brii Bio for up to $33M, reducing K2HV debt from $50M to $17M.","Cash $23.7M at Dec 31, 2023 (down from $62.6M); net loss $92.8M ($6.03/share) vs $113.3M in 2022.","R&D expense $9.3M (down 40%), SG&A $42.1M (down 25%) after April 2023 workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014743","json":"https://secwatch.observer/filing/0001493152-24-014743.json","markdown":"https://secwatch.observer/filing/0001493152-24-014743.md","text":"https://secwatch.observer/filing/0001493152-24-014743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/0001493152-24-014743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:38:16.563444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de7af734ca92fb37f644c49cdbe67cf0c0165cb5","claim":"VBI Vaccines Inc/BC reported the year ended December 31, 2023 results: revenue $3.1 million.","evidence_excerpt":"Product revenue, net of $3.1 million in 2023 compared to $0.9 million in 2022, a 234% year-over-year increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/0001493152-24-014743-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$3.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}